FDA Reverses Course, Will Allow Amicus to Submit Fabry Disease NDA

Drug Industry Daily
A A
The FDA has accepted Amicus Therapeutics’ submission of its rare disease drug for review, a reversal from its decision under the Obama administration.

To View This Article:

Login

Subscribe To Drug Industry Daily